Pulse Biosciences Inc (PLSE) Financial Statements (2026 and earlier)

Company Profile

Business Address 3957 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:80,735118,03844,36561,13928,60012,463
Cash and cash equivalent80,735118,03844,36561,13928,61412,463
Other undisclosed cash, cash equivalents, and short-term investments     (14) 
Receivables274   61 
Inventory, net of allowances, customer advances and progress billings136   5,824 
Inventory136   5,824 
Other undisclosed current assets2,2761,4119631,0082,1459,876
Total current assets:83,421119,44945,32862,14736,63022,339
Noncurrent Assets
Operating lease, right-of-use asset6,0107,1637,2568,0628,7859,438
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,0511,1601,5281,9612,4622,478
Intangible asset, including goodwill, after accumulated amortization3,3664,0114,6775,3426,0076,673
Goodwill2,7912,7912,7912,7912,7912,791
Intangible asset, excluding goodwill, after accumulated amortization5751,2201,8862,5513,2163,882
Other noncurrent assets691677365365365365
Total noncurrent assets:11,11813,01113,82615,73017,61918,954
TOTAL ASSETS:94,539132,46059,15477,87754,24941,293
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,3538,7005,6504,1687,2937,043
Accounts payable2,7771,6731,8361,5732,9041,717
Accrued liabilities3,5767,0273,8142,5954,3895,326
Deferred revenue     16 
Debt     436 
Due to related parties✕✕✕✕917  
Other undisclosed current liabilities1,5701,3551,058896774542
Total current liabilities:7,92310,0556,7085,9818,5197,585
Noncurrent Liabilities
Long-term debt and lease obligation:     10,04010,814
Liabilities, other than long-term debt5,9607,5438,0869,144  
Operating lease, liability5,9607,5438,0869,14410,04010,814
Other undisclosed noncurrent liabilities    65,000(10,040)(10,814)
Total noncurrent liabilities:5,9607,5438,08674,14410,04010,814
Total liabilities:13,88317,59814,79480,12518,55918,399
Equity
Equity, attributable to parent80,656114,86244,360(2,248)35,69022,894
Common stock686655372925
Additional paid in capital543,869505,296381,220292,420271,861195,410
Accumulated other comprehensive loss      (1)
Accumulated deficit(463,281)(390,500)(336,915)(294,705)(236,200)(172,540)
Total equity:80,656114,86244,360(2,248)35,69022,894
TOTAL LIABILITIES AND EQUITY:94,539132,46059,15477,87754,24941,293

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues350  7001,418114
Net investment income      114
Cost of revenue(539)  (11,944)(1,968)(500)
Cost of product and service sold    (8,477)(600)(500)
Gross profit:(189)  (11,244)(550)(386)
Operating expenses(76,750)(56,257)(43,574)(46,813)(62,464)(49,965)
Other undisclosed operating income      500
Operating loss:(76,939)(56,257)(43,574)(58,057)(63,014)(49,851)
Nonoperating income (expense)4,1582,6721,364(448)(646)(5)
Investment income, nonoperating     (13)(5)
Interest and debt expense      
Other undisclosed income from continuing operations before equity method investments, income taxes      5
Loss from continuing operations before equity method investments, income taxes:(72,781)(53,585)(42,210)(58,505)(63,660)(49,851)
Other undisclosed income from continuing operations before income taxes145,581     
Income (loss) from continuing operations before income taxes:72,800(53,585)(42,210)(58,505)(63,660)(49,851)
Income tax expense      (3)
Income (loss) from continuing operations:72,800(53,585)(42,210)(58,505)(63,660)(49,854)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(63,660)(49,854)
Net income (loss):72,800(53,585)(42,210)(58,505)(63,660)(49,854)
Other undisclosed net income (loss) attributable to parent(145,581)    3
Net loss available to common stockholders, diluted:(72,781)(53,585)(42,210)(58,505)(63,660)(49,851)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):72,800(53,585)(42,210)(58,505)(63,660)(49,854)
Comprehensive income (loss):72,800(53,585)(42,210)(58,505)(63,660)(49,854)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(145,581)   1(2)
Comprehensive loss, net of tax, attributable to parent:(72,781)(53,585)(42,210)(58,505)(63,659)(49,856)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: